Dr Vanessa Estall
BHB, MBChB, FRANZCR, MD, Radiation Oncologist
Languages spoken
English
Overview
Clinical interest in skin/melanoma, head and neck, CNS, lung, lymphoma and palliative.
Dr Vanessa Estall is an empathetic, experienced clinician, with a focus on evidence-based practice. She completed specialist Radiation Oncology training in Australia in 2007, and a Research Fellowship at Addenbrookes Hospital Cambridge UK in 2009. Her work assessed the highly precise and novel radiation treatment for skull base tumours, and she was awarded a Doctorate of Medicine (MD).
She has since worked in large treatment centres in NSW and Victoria, gaining specialist skills in stereotactic radiosurgery, Skin/Melanoma, Central Nervous System (CNS), Head and Neck, and Lung cancers and plus palliative care. radiotherapy.
She is active in research, teaching, quality assurance, governance, and leadership. She has led multiple multidisciplinary clinical teams, is a clinical supervisor in the training of future radiation oncologists and has held leadership positions in the Royal Australian and New Zealand College of Radiology (RANZCR) including Chief Accreditation Officer for Specialist Training (2018-2023).
Research interests
- Glioma imaging
- Skull base tumours
- Skin/melanoma
- Head and Neck
Professional memberships
- European Society of Radiation Oncology (ESTRO)
- Trans-Tasman Radiation Oncology Group (TROG)
- Australia and New Zealand Melanoma Trials Group (ANZMTG)
- Cooperative Trials Group for Neuro-Oncology (COGNO)
- Clinical Oncology Society of Australia (COSA)
Publications
- Bucknell N, Gyorki D, Bressel M, Estall V, Webb A, Henderson M, Chua M, Rischin D, Tiong A. Cutaneous squamous cell carcinoma metastatic to axilla and groin: Outcomes and prognostic factors. Aus J Derm Online Nov 2021
- Wang W, Smith JL, Carlino MS, Burmeister B, Pinkham MB, Fogarty GB, Christie D, Estall V, Shackleton M, Clements A, Wolfe R, Thao L, Pation EJ, Steel V, Williams NC. Phase I/II trial of concurrent extracranial palliative radiation therapy with Dabrafenib and Trametinib in metastatic BRAF V600E/K mutation-positive cutaneous Melanoma. Clin Trans Rad Onc Sept;30:95-99.
- Wang TW, Smith LJ, Carlino M, Burmeister B, Pinkham MB, Fogarty GB, Christie D, Estall V, Shackleton M, Wolfe R, Phuong TLT, Paton EJ, Steel V, Williams NC. Evaluating the Safety and Tolerability of the Combination of Dabrafenib, Trametinib and Palliative Radiotherapy in Patients with Metastatic BRAF V600E/K Mutation-positive Cutaneous Melanoma. IJROBP 2020 Nov;108(3):S133-4.
- Slape DR, Saunderson RB, Tatian AH, Forstner DF, Estall VJ. Cutaneous malignancies in Indigenous Peoples of urban Sydney. J Med Imaging Radiat Oncol. 2019 Apr;63(2):244-9.
- Sood A, Wykes J, Roshan D, Wang LY, McGuinness J, Forstner D, Fowler A, Lee M, Kernohan M, Ngo Q, Estall V, Ebrahimi A. Number of nodal metastases and prognosis in metastatic cutaneous squamous cell carcinoma of the head and neck. ANZ J Surg 2019 Jul;89(7-8):863-7.